Patents Assigned to KaNDy Therapeutics Limited
  • METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE
    Publication number: 20230382922
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl) hexahydropyrazino [2,1-c] [1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Application
    Filed: July 31, 2023
    Publication date: November 30, 2023
    Applicant: KaNDy Therapeutics Limited
    Inventors: Mike TROWER, Monica LAZARO, Derek BUSH, David ELDER, Mary KERR
  • Method of treating certain sex hormone-dependent diseases administering a soft gelatin capsule comprising NK1 and NK3 receptors antagonists
    Patent number: 11787820
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: October 17, 2023
    Assignee: KaNDy Therapeutics Limited
    Inventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
  • Method of treatment of symptoms of menopause
    Patent number: 11767328
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Grant
    Filed: January 13, 2023
    Date of Patent: September 26, 2023
    Assignee: KaNDy Therapeutics Limited
    Inventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
  • METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE
    Publication number: 20230174552
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Application
    Filed: January 13, 2023
    Publication date: June 8, 2023
    Applicant: KaNDy Therapeutics Limited
    Inventors: Mike TROWER, Monica LAZARO, Derek BUSH, David ELDER, Mary KERR
  • Method of treatment of symptoms of menopause
    Patent number: 11591346
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: February 28, 2023
    Assignee: KaNDy Therapeutics Limited
    Inventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
  • NEW CHEMICAL PROCESS FOR MAKING 6-CHLORO-4-(4-FLUORO-2-METHYLPHENYL)PYRIDIN-3-AMINE A KEY INTERMEDIATE OF NT-814
    Publication number: 20230002322
    Abstract: The invention relates to a new process for producing compound 2-(3,5-bis(trifluoromethyl)phenyl)-N-(6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-yl)-N,2-dimethylpropanamide (Compound IX) which is useful in the manufacture of compound 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide (Compound A).
    Type: Application
    Filed: November 9, 2020
    Publication date: January 5, 2023
    Applicant: KaNDy Therapeutics Limited
    Inventors: Marcel SCHLEUSNER, Massimo GHIZZONI, Ron LAWRENCE
  • NOVEL USES
    Publication number: 20210236506
    Abstract: This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.
    Type: Application
    Filed: February 10, 2021
    Publication date: August 5, 2021
    Applicant: KaNDy Therapeutics Limited
    Inventor: Mike Trower
  • NOVEL USES
    Publication number: 20210128574
    Abstract: This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.
    Type: Application
    Filed: November 6, 2018
    Publication date: May 6, 2021
    Applicant: KaNDy Therapeutics Limited
    Inventor: Mike Trower
  • METHOD OF TREATING CERTAIN SEX HORMONE-DEPENDENT DISEASES ADMINISTERING A SOFT GELATIN CAPSULE COMPRISING NK1 AND NK3 RECEPTORS ANTAGONISTS
    Publication number: 20200361957
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Application
    Filed: August 4, 2020
    Publication date: November 19, 2020
    Applicant: KaNDy Therapeutics Limited
    Inventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
  • METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE
    Publication number: 20200361956
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis (trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Application
    Filed: August 4, 2020
    Publication date: November 19, 2020
    Applicant: KaNDy Therapeutics Limited
    Inventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
  • Soft gelatin capsule formulation
    Patent number: 10774091
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: September 15, 2020
    Assignee: KaNDy Therapeutics Limited
    Inventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
  • NOVEL PHARMACEUTICAL FORMULATION
    Publication number: 20190284205
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Application
    Filed: March 13, 2019
    Publication date: September 19, 2019
    Applicant: KaNDy Therapeutics Limited
    Inventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr